Approved indications: Oravig is approved for the local treatment of oropharyngeal candidiasis (oral thrush) in adults, including those with conditions such as HIV infection or head and neck cancer receiving radiation.

Off-label uses: Oravig is not commonly used for other fungal infections; systemic or other topical azole antifungals (such as fluconazole or clotrimazole troches) are typically preferred for off-label situations, so evidence for off-label use of Oravig itself is limited.

Efficacy expectations:

• Symptoms such as soreness, white patches, and difficulty swallowing often begin to improve within a few days, but the full 14-day course is usually needed for best results.
• Clinical trials show high rates of clinical cure or marked improvement in most patients, with outcomes comparable to other local therapies like clotrimazole troches when taken as directed.
• Compared with oral fluconazole, Oravig provides similar symptom relief for mild to moderate oral thrush but acts locally with lower systemic exposure, which may reduce the risk of systemic side effects and drug interactions.

Typical dosing: For adults and adolescents 16 years and older, the usual dose is one 50 mg Oravig buccal tablet applied once daily to the upper gum (canine fossa) for 14 consecutive days.

How to apply:

• In the morning after brushing your teeth, with dry hands remove one tablet from the bottle.
• Place the rounded side of the tablet against the upper gum just above a front side tooth (incisor/canine area) and hold it in place by pressing the upper lip over it for about 30 seconds until it sticks.
• Once applied, leave the tablet in place; it will slowly dissolve over about 6 hours or longer and may adhere to gum, inner lip, or cheek.
• You may eat and drink normally, but avoid chewing gum, touching or pressing the tablet, vigorous mouth rinsing, or using upper dentures that interfere with the tablet.
• Alternate the side of the mouth where you place the tablet each day, and remove any remaining pieces before applying the next dose.

Special instructions if the tablet falls off or is swallowed:

• If it does not stick or falls off within the first 6 hours, try to reposition the same tablet; if it still will not adhere, replace it with a new tablet.
• If you swallow the tablet within the first 6 hours, drink a glass of water and apply one new tablet only once.
• If it falls off or is swallowed after it has been in place for 6 hours or more, do not apply another tablet until the next scheduled dose.

Missed dose guidance: If you miss a dose, apply it as soon as you remember unless it is almost time for the next dose; in that case skip the missed dose and resume your regular schedule, without using extra tablets.

Overdose: Clinically significant overdose is unlikely because systemic absorption is low, but swallowing multiple tablets may increase exposure; management is usually supportive, and emergency care or a poison control center can provide specific advice.

Common side effects:

• Local mouth and gum reactions (discomfort, burning, pain, swelling, ulcers, altered or reduced taste, dry mouth, toothache) are among the most frequent and are usually mild to moderate, often occurring early in treatment.
• Gastrointestinal symptoms such as diarrhea, nausea, vomiting, or upper abdominal pain, and headache can occur but are generally uncommon and self-limited.

Serious or rare adverse effects:

• Allergic or hypersensitivity reactions, including rash, hives, swelling of the face, lips, tongue, or throat, trouble breathing or swallowing, or severe mouth swelling or pain, require immediate medical attention and permanent discontinuation.
• Because systemic absorption is very low, systemic toxicity is rare, but clinically significant bleeding has been reported when miconazole products are used with warfarin.

Warnings and precautions:

• Allergy: Do not use if you have known hypersensitivity to miconazole, other components of the tablet, or milk protein concentrate.
• Age limits: Safety and efficacy are not established in children under 16 years, and use in younger children is discouraged due to choking risk.
• Liver disease: Miconazole is metabolized in the liver; although systemic exposure from Oravig is minimal, use cautiously in hepatic impairment.
• Kidney disease: No dose adjustment is usually needed, as very little unchanged drug is excreted in urine.
• Pregnancy: Animal data suggest potential fetal risk at high systemic doses; Oravig should be used during pregnancy only if clearly needed.
• Breastfeeding: It is not known if miconazole from Oravig passes into human milk; consider the benefits of breastfeeding and the mother’s need for treatment.

Relative safety compared with other therapies: Because Oravig delivers low systemic levels of miconazole, it generally has fewer systemic side effects and interactions than oral systemic azoles (such as fluconazole), but local mouth reactions and the risk of warfarin interaction still require attention.

Side-effect reporting and safety updates: Adverse effects can be reported to the manufacturer’s phone number on the package or directly to the FDA MedWatch program (online or by phone), where ongoing safety communications about Oravig are also available.

Drug interactions:

• Warfarin and other anticoagulants: Miconazole can enhance the effect of warfarin, increasing bleeding risk; if used together, closer monitoring of INR or other coagulation tests and watching for bleeding (bruising, nosebleeds, blood in urine or stool) is important.
• CYP2C9 and CYP3A4 substrates: Because miconazole inhibits these enzymes, there is potential (though reduced by low systemic levels) to increase levels of drugs such as some oral diabetes medicines, phenytoin, certain ergot migraine drugs, and other narrow-therapeutic-index medications; clinicians may adjust doses or monitor more closely.
• Other prescription/OTC drugs and supplements: Many medicines can theoretically interact, so all current drugs, vitamins, and herbal products should be reviewed before starting Oravig.
• Food and alcohol: No specific food restrictions are required; moderate alcohol is not known to interact directly with Oravig but can impair immunity and healing if excessive.

Precautions and conditions where use may be unsafe or need caution:

• History of allergy to miconazole, milk proteins, or other azole antifungals.
• Liver disease, where even small increases in drug exposure may be more significant.
• Use with strong anticoagulants or other high-risk interacting drugs without appropriate monitoring.
• Children under 16 years or people with swallowing difficulties or high choking risk.

Monitoring needs:

• Patients on warfarin or similar anticoagulants may need more frequent INR or clotting tests when Oravig is started or stopped.
• Patients on interacting CYP2C9/3A4 drugs (for example, some diabetes medicines, phenytoin, or ergot alkaloids) may require clinical monitoring for increased effects or side effects and occasional blood tests as guided by their clinician.
• Routine blood tests are not usually required for otherwise healthy patients, given the minimal systemic absorption.

Q: What does Oravig treat?
A: Oravig treats oropharyngeal candidiasis (oral thrush), a yeast infection in the mouth and throat, by delivering the antifungal medicine miconazole directly to the affected area.

Q: How long does it take for Oravig to start working?
A: Many people notice symptom improvement within a few days, but the full 14-day course is usually needed to completely clear the infection and reduce the chance of relapse.

Q: Can I eat and drink while the Oravig tablet is in my mouth?
A: Yes, you can eat and drink normally, but you should avoid chewing gum, touching or pressing the tablet, vigorous rinsing, or using upper dentures that interfere with the tablet so it stays in place.

Q: What should I do if the Oravig tablet falls off or I swallow it?
A: If it falls off or is swallowed within the first 6 hours, try to reposition the same tablet or replace it once, but if it comes off after 6 hours, wait until the next scheduled dose before applying another tablet.

Q: Is Oravig safe to use with my other medications, especially blood thinners?
A: Oravig can interact with warfarin and some other medicines by increasing their levels or effects, so your clinician may need to review all your medicines and monitor blood tests such as INR if you use Oravig with a blood thinner.

Q: Can children use Oravig for oral thrush?
A: Oravig has not been shown to be safe or effective in children under 16 years, and younger children also have a higher choking risk from the buccal tablet, so other treatments are usually chosen.

Q: What happens if I stop Oravig as soon as I feel better?
A: Stopping early can allow some yeast to survive, which may cause the infection to come back and could contribute to reduced response to similar medicines later, so the entire prescribed course should be completed.

Storage: Store Oravig at room temperature (68°F to 77°F / 20°C to 25°C), protect it from moisture, keep the tablets in the original closed bottle, and keep out of the reach of children.

Disposal: If treatment is finished or tablets are no longer needed, dispose of unused tablets in the household trash in a secure container or mixed with undesirable material (such as coffee grounds), and do not flush them down the toilet unless specifically instructed.